Modified FOLFIRINOX ‘recommended adjuvant regimen’ for patients with pancreatic cancer

September 1, 2022

Adjuvant chemotherapy with modified FOLFIRINOX resulted in significantly longer survival vs. gemcitabine among patients with previously resected pancreatic ductal adenocarcinoma, according to 5-year data from a randomized phase 3 study.Results of the PRODIGE 24/Canadian Cancer Trials Group PA6 trial — published in JAMA Oncology showed improvement in DFS, OS, metastasis-free survival and cancer-specific survival across all predefined subgroups.Surgical excision of pancreatic ductal adenocarcinoma is potentially curative, but the 5-year OS rate for surgery alone is approximately 10%,Read More

Categories: News

Related Articles

Neoadjuvant chemotherapy regimen extends survival in pancreatic cancer

Neoadjuvant modified FOLFIRINOX alone vs. with hypofractionated radiotherapy demonstrated favorable OS among patients with borderline resectable pancreatic cancer, according to results of a phase 2…

Nimotuzumab plus gemcitabine prolongs survival in KRAS wild-type pancreatic cancer

CHICAGO — The addition of nimotuzumab to gemcitabine prolonged OS and PFS among patients with KRAS wild-type locally advanced or metastatic pancreatic cancer, according to…

Tislelizumab plus chemotherapy significantly extends OS in advanced esophageal cancer

The addition of tislelizumab to chemotherapy significantly extended OS for patients with previously untreated advanced esophageal squamous cell carcinoma, according to a press release from…

2018 FGS Annual Meeting Registration Is Now Open!

Registration for the 2018 FGS Annual Meeting is now open! We will be returning to the Hyatt Regency Grand Cypress this September 14-16, 2018. Short…

Justin Bouck May 22, 2018

Tislelizumab regimen extends OS in advanced esophageal cancer

The addition of tislelizumab to first-line chemotherapy extended OS among patients with advanced esophageal cancer, according to study results presented at European Society for Medical…